Evidence map›Paper›PMID 36002960›Full record

ArticleNeuroImage. Clinical2022

Longitudinal changes of deep gray matter shape in multiple sclerosis.

Charidimos Tsagkas, Emanuel Geiter, Laura Gaetano, Yvonne Naegelin, Michael Amann, Katrin Parmar, Athina Papadopoulou, Jens Wuerfel, Ludwig Kappos, Till Sprenger and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NeuroImage. Clinical, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Heterogeneous Deep Gray Matter Iron Deposition Patterns across Multiple Sclerosis Subgroups Defined by the Clinico-Radiological Paradox.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Charidimos TsagkasNeurologic Clinic and Policlinic, Departments of Medicine, Clinical Research and Biomedical Engineering, Department of Neurology, University Hospital Basel and University of Basel, Basel, Switzerland; Translational Imaging in Neurology (ThINK) Basel, Department of Medicine and Biomedical Engineering, University Hospital Basel and University of Basel, Basel, Switzerland. Electronic address: charidimos.tsagkas@usb.ch.
Emanuel GeiterMedical Image Analysis Center AG, Basel, Switzerland. Electronic address: emanuel.geiter@miac.ch.
Laura GaetanoF. Hoffmann-La Roche Ltd, Basel, Switzerland. Electronic address: laura.gaetano@roche.com.
Yvonne NaegelinNeurologic Clinic and Policlinic, Departments of Medicine, Clinical Research and Biomedical Engineering, Department of Neurology, University Hospital Basel and University of Basel, Basel, Switzerland. Electronic address: Yvonne.Naegelin@usb.ch.
Michael AmannNeurologic Clinic and Policlinic, Departments of Medicine, Clinical Research and Biomedical Engineering, Department of Neurology, University Hospital Basel and University of Basel, Basel, Switzerland; Medical Image Analysis Center AG, Basel, Switzerland; Department of Biomedical Engineering, University of Basel, Basel, Switzerland. Electronic address: michael.amann@miac.ch.
Katrin ParmarNeurologic Clinic and Policlinic, Departments of Medicine, Clinical Research and Biomedical Engineering, Department of Neurology, University Hospital Basel and University of Basel, Basel, Switzerland; Reha Rheinfelden, Rheinfelden, Switzerland. Electronic address: K.Parmar@reha-rhf.ch.
Athina PapadopoulouNeurologic Clinic and Policlinic, Departments of Medicine, Clinical Research and Biomedical Engineering, Department of Neurology, University Hospital Basel and University of Basel, Basel, Switzerland; Translational Imaging in Neurology (ThINK) Basel, Department of Medicine and Biomedical Engineering, University Hospital Basel and University of Basel, Basel, Switzerland. Electronic address: athina.papadopoulou@usb.ch.
Jens WuerfelMedical Image Analysis Center AG, Basel, Switzerland; Department of Biomedical Engineering, University of Basel, Basel, Switzerland. Electronic address: jw@miac.ch.
Ludwig KapposNeurologic Clinic and Policlinic, Departments of Medicine, Clinical Research and Biomedical Engineering, Department of Neurology, University Hospital Basel and University of Basel, Basel, Switzerland; Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Medicine, Clinical Research and Biomedical Engineering, University Hospital Basel and University of Basel, Basel, Switzerland. Electronic address: ludwig.kappos@usb.ch.
Till SprengerNeurologic Clinic and Policlinic, Departments of Medicine, Clinical Research and Biomedical Engineering, Department of Neurology, University Hospital Basel and University of Basel, Basel, Switzerland; Department of Neurology, DKD HELIOS Klinik Wiesbaden, Wiesbaden, Germany. Electronic address: tillsprenger@gmx.de.
Cristina GranzieraNeurologic Clinic and Policlinic, Departments of Medicine, Clinical Research and Biomedical Engineering, Department of Neurology, University Hospital Basel and University of Basel, Basel, Switzerland; Translational Imaging in Neurology (ThINK) Basel, Department of Medicine and Biomedical Engineering, University Hospital Basel and University of Basel, Basel, Switzerland; Department of Biomedical Engineering, University of Basel, Basel, Switzerland. Electronic address: cristina.granziera@usb.ch.
M Mallar ChakravartyCerebral Imaging Centre-Douglas Mental Health University Institute, Verdun, QC, Canada; Department of Biomedical Engineering, McGill University, Montreal, QC, Canada; Department of Psychiatry, McGill University, Montreal, QC, Canada.
Stefano MagonNeurologic Clinic and Policlinic, Departments of Medicine, Clinical Research and Biomedical Engineering, Department of Neurology, University Hospital Basel and University of Basel, Basel, Switzerland; Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland. Electronic address: stefano.magon@roche.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aimed to investigate longitudinal deep gray matter (DGM) shape changes and their relationship with measures of clinical disability and white matter lesion-load in a large multiple sclerosis (MS) cohort. MATERIALS AND

methodsA total of 230 MS patients (179 relapsing-remitting, 51 secondary progressive; baseline age 44.5 ± 11.3 years; baseline disease duration 12.99 ± 9.18) underwent annual clinical and MRI examinations over a maximum of 6 years (mean 4.32 ± 2.07 years). The DGM structures were segmented on the T1-weighted images using the "Multiple Automatically Generated Templates" brain algorithm. White matter lesion-load was measured on T2-weighted MRI. Clinical examination included the expanded disability status scale, 9-hole peg test, timed 25-foot walk test, symbol digit modalities test and paced auditory serial addition test. Vertex-wise longitudinal analysis of DGM shapes was performed using linear mixed effect models and evaluated the association between average/temporal changes of DGM shapes with average/temporal changes of clinical measurements, respectively.

resultsA significant shrinkage over time of the bilateral ventrolateral pallidal and the left posterolateral striatal surface was observed, whereas no significant shape changes over time were observed at the bilateral thalamic and right striatal surfaces. Higher average lesion-load was associated with an average inwards displacement of the global thalamic surface with relative sparing on the posterior side (slight left-side predominance), the antero-dorso-lateral striatal surfaces bilaterally (symmetric on both sides) and the antero-lateral pallidal surface (left-side predominance). There was also an association between shrinkage of large lateral DGM surfaces with higher clinical motor and cognitive disease severity. However, there was no correlation between any DGM shape changes over time and measurements of clinical progression or lesion-load changes over time.

conclusionsThis study showed specific shape change of DGM structures occurring over time in relapse-onset MS. Although these shape changes over time were not associated with disease progression, we demonstrated a link between DGM shape and the patients' average disease severity as well as white matter lesion-load.

Indexed as

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingWhite MatterAdultAtrophyBrainGray MatterHumansMagnetic Resonance ImagingMiddle AgedAtrophyDeep gray matterMultiple sclerosisNeurodegenerationNeuroimagingShape

Identifiers

PMID36002960
PMCPMC9421532

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.